Additional long-term data from Orchard Therapeutics has convinced Ireland, the Netherlands and Belgium to reimburse the company’s costly gene therapy Libmeldy (atidarsagene autotemcel). The three countries, working together under the BeNeLuxA cross-country initiative, had previously said the drug was too expensive.
“We are pleased to have reached an agreement with the BeNeluxA consortium that enables sustainable access to treatment. The agreement...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?